Navigation Links
HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study
Date:7/19/2010

The BC Centre of Excellence in HIV/AIDS (BC-CfE) published an important study today in the globally respected Lancet medical journal. The study strongly reinforces the view that the benefits of highly active antiretroviral therapy (HAART) extend beyond treatment of the virus to significantly preventing the transmission and spread of HIV.

Recognized as the gold standard treatment for HIV, HAART uses a combination of drugs to stop HIV from progressing to AIDS, extends life expectancy, and significantly reduces HIV-related deaths in diagnosed individuals.

"The expansion of HAART treatment plays an important role in the health of British Columbians with HIV, preventing HIV transmission and maximizing public health resources," said Gordon Campbell, Premier of British Columbia. "Based on HAART's effectiveness and ongoing research at the BC-CfE, Canada's leading HIV/AIDS organization, the government of B.C. is investing in improving access to HAART through innovative programs such as the Seek and Treat initiative."

The new study, funded by the U.S. National Institute on Drug Abuse (NIDA), found that increased levels of HAART treatment were associated with a decrease in community viral load and in new HIV diagnoses across British Columbia, particularly in populations with a history of injection drug use.

"These study results reinforce the effectiveness of HAART in preventing transmission of HIV, and support extending the treatment as prevention model developed at the BC-CfE and now being rolled out in major centres in Canada, the U.S. and elsewhere," said Dr. Julio Montaner, study lead author and BC-CfE director. Montaner is also a professor and chair in AIDS research at the University of British Columbia and President of the International AIDS Society (IAS).

"This BC-CfE study suggests expanded HAART coverage may curb the spread of HIV," said NIDA Director Dr. Nora D. Volkow. "These findings are especially important when it comes to populations with a history of injection drug use, as we now have a tool to help reduce the spread of HIV among them."

Results of mathematical models have varied dramatically in their estimation of the potential impact of increased HAART coverage on HIV transmission, predicting anywhere from elimination to potential worsening of the HIV epidemic. Therefore, the present study was conducted to analyze, at the population level, the potential association between the expansion of HAART, viral load and new HIV diagnoses per year in a Canadian province with free access to HIV care. The population was then stratified for injection drug use status.

Data resulting from BC-CfE research showed that the number of individuals actively receiving HAART had a strong impact on overall viral load and new diagnoses in the community. As HAART coverage increased, new HIV diagnoses decreased; as HAART coverage stabilized, so too did viral load and new HIV diagnoses.

The expansion of HAART is proving to be an important prevention tool that complements efforts of community prevention programs in B.C. programs working to educate people about HIV and deliver needle-exchange and harm reduction supplies for at-risk populations.

The study results align with the emphasis global leaders in HIV research, policy and advocacy place on early treatment to prevent transmission of HIV. Michel Sidib, Executive Director of UNAIDS, the Joint United Nations Programme on HIV/AIDS, noted that treatment is a smart health investment, as it reduces HIV transmission, TB infection and maternal and child mortality within communities, and improves work productivity.

"The most recent evidence presented by the BC Centre for Excellence in HIV/AIDS and other leading research organizations supports these facts and tells us that we need to introduce treatment earlier," said Sidib. "Treatment not only saves lives, it can be one of the most compelling prevention tools we have."

The B.C. government recently invested in a $48-million, four-year pilot project to provide HAART treatment to people in medical need, living with HIV, but not currently accessing the health system in Prince George and Vancouver. The program, called Seek and Treat, will improve access to HIV/AIDS medications among hard-to-reach populations in these two communities such as sex trade workers, injection drug users and men who have sex with men. The pilot is currently being evaluated as part of the BC-CfE's innovative research program, Seek and Treat for the Optimal Prevention of HIV/AIDS (STOP HIV/AIDS).

Currently, more than 33 million people worldwide are infected with HIV, at least 7,400 people become infected with HIV each day and nearly 5,500 die daily from an AIDS-related illness.


'/>"/>

Contact: Brian Lin
brian.lin@ubc.ca
604-822-2234
University of British Columbia
Source:Eurekalert

Related medicine news :

1. HIV care providers and researchers applaud release of national HIV/AIDS strategy
2. Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
3. Positive prevention toolkit aims to assist global training of HIV/AIDS caregivers
4. March 10 is National Women and Girls with HIV/AIDS Awareness Day
5. New discovery brings hope to treatment of incurable blood cancer
6. Shoulder arthritis? What patients need to know before treatment
7. Rare Blood Vessel Disease Could Have New Treatment Option
8. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
9. New treatment for crippling diabetic Charcot foot
10. Arsenic shows promise as cancer treatment, Stanford study finds
11. Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Today, ... optimize the ingestion of their medication by matching users with high quality water pipes ... compare pieces with no commitment. , Inhale was founded by two brothers, Nick and ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: